Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 16, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Prostatic stromal sarcoma with neuroectodermal differentiation.

Hitoshi Yamazaki¹, Teppei Ohyama, Toshiki Tsuboi

¹Department of Pathology, Medical center hospital, Kitasato Institute, Kitasato University, Saitama, Japan. powder1104@hotmail.com

Diagnostic Pathology

|December 11, 2012

Summary

Prostatic stromal sarcoma is a rare cancer. This case highlights unique immunohistochemical markers, suggesting potential neuroectodermal differentiation in this rare prostatic tumor.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bladder paraganglioma with lymph node metastasis treated by surgery with long-term recurrence-free survival: A case report.

Urology case reports·2026

Same author

Long-term outcomes of combination therapy with stereotactic body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors ≥2 cm.

PloS one·2025

Same author

Dynamics of color vision recovery in Vogt-Koyanagi-Harada disease: a longitudinal study using cone contrast test and adaptive optics imaging.

Journal of ophthalmic inflammation and infection·2025

Same author

Erratum: <i>In vivo</i> efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.

Molecular therapy. Nucleic acids·2025

Same author

<i>In vivo</i> efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney.

Molecular therapy. Nucleic acids·2025

Same author

Compared to Trabeculectomy, Ex-Press<sup>®</sup> Surgery Significantly Decreased the Loss of Corneal Endothelial Cell Density in Low-Intraocular-Pressure Glaucoma: 3-Year Follow-Up.

Clinical ophthalmology (Auckland, N.Z.)·2024

Area of Science:

Oncology
Pathology
Urology

Background:

Prostatic stromal sarcoma is an exceptionally rare malignancy, accounting for only 0.1-0.2% of all prostate cancers.
The rarity of this tumor leads to limited understanding of its detailed characteristics and behavior.

Observation:

A case study of a 63-year-old male presenting with urinary obstructive symptoms due to prostatic stromal sarcoma is detailed.
Initial diagnosis was neuroendocrine carcinoma, but subsequent histopathology and immunohistochemistry revealed a distinct profile.

Findings:

The tumor cells showed characteristic immunohistochemical staining, including positivity for vimentin, CD56, CD99, and focal positivity for synaptophysin, CD10, progesterone receptor, desmin, and CD34.
Unlike previously reported cases, this tumor uniquely expressed CD56, CD99, and synaptophysin.

Related Experiment Videos

Last Updated: May 16, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Implications:

This case presents the first documented prostatic stromal sarcoma with a specific immunohistochemical profile.
The findings suggest that prostatic stromal sarcoma may exhibit neuroectodermal differentiation, warranting further investigation into its biological characteristics.